

EXTENDED SPECTRUM B-LACTAMASES IN URINARY ISOLATES OF *ESCHERICHIA COLI* IN FIVE IRANIAN HOSPITALS

JAFAR MOBALEGHI¹, HEIMAN SALIMIZAND², SOHEILA BEIRANVAND³, SHAHO MEMBARI⁴, AND ENAYAT KALANTAR^{*5-6}

¹Department of Surgery, Beasat hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran, ²Microbiology Laboratory, Beasat hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran, ³Gods Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran, ⁴ Department of Microbiology, School of Paramedical Sciences, Kurdistan University of Medical Sciences, Sanandaj, Iran. ⁵ School of Health, Environmental Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran. Department of Pathobiology, Alborz University of Medical Sciences, Karaj, Iran. Email: kalantar_enayat@yahoo.com

Received: 17 November 2011, Revised and Accepted: 28 January 2012

ABSTRACT

Background: Urinary tract infections caused by *Escherichia coli* have become a significant global public health problem with Kurdistan being no exception. Furthermore, the situation is worsening due to advent of increased antibiotic resistance.

Aims: The wide spread presence of antibiotic resistant *E. coli* in our environment necessitates regular monitoring of antibiotics susceptibility trends in the clinical isolates obtained from different regions to provide the basis for developing Local, National and International prescription programs that can be used for delineating guidelines to maintain the desired effectiveness of antibiotics.

Materials and Methods: Urine samples from five hospital microbiology laboratories were analyzed for isolation and identification of *E. coli*. *E. coli* PTCC 1533 was sent to them as a positive control for antimicrobial susceptibility testing.

Antibiotic susceptibility of *E. coli* isolates were validated following the Kirby-Bauer disc diffusion technique using Muller Hinton agar. Screening test for ESBL was done according to the criteria recommended by CLSI.

Results: A total of 1257 *E. coli* strains were isolated from patients who suffer from UTI referred to five hospitals in Kurdistan province. The most resistant antibiotics tested against *E. coli* were penicillin, ampicillin, and amoxicillin. All the *E. coli* isolates were tested for ESBL production and 239 (19.02%) were found to be ESBL producers.

Conclusions - In conclusion, our study reinforces the necessity for appropriate use of antibacterial compounds, and with the technical ability we now have to see resistance at a genetic level, to monitor more detailed patterns of emergence.

Keywords: Antimicrobial resistance, *E. coli*, Urinary tract infection, Kurdistan

INTRODUCTION

Urinary tract infections (UTIs) having as etiologic agent *Escherichia coli* are common infections with an estimated annual global incidence of at least 250 million cases, being costly to both patients and health care funding system¹.

This important opportunistic pathogen that has shown an increasing antimicrobial resistance to most antibiotics²⁻³ isolated from humans. It has been observed that antibiotic susceptibility of bacterial isolates is not constant, but dynamic and varies with time and environment⁴.

The therapeutic steps during the treatment of UTIs, involves a short course of antimicrobial drug, such as antibiotics viz. ampicillin, chloramphenicol, colistin methane sulphonate, kanamycin, nalidixic acid, nitrofurantoin, streptomycin, norfloxacin, Trimethoprim-Sulfamethoxazole etc. The antibiotic resistance studies using urinary tract isolates of *E. coli* from patients have been reported to have shown increased resistance to certain antibiotics, particularly, Extended-Spectrum-Beta-Lactamase (ESBL). These organisms are now one of the main gram-negative species to cause infections with ESBL-positive bacteria in humans⁵⁻⁶.

The increase of drug resistance among these organisms has made therapy of UTI difficult and has led to greater use of expensive broad spectrum antibiotics such as third generation of cephalosporin. Therefore, systematic monitoring of such resistance at local, national and international levels is recognized as an integral part of the control strategy by most national and international organizations including World Health Organization⁷⁻⁸.

To satisfy the urgent need for an efficient surveillance system to monitor the possible impact of this policy, and to define current occurrence and phenotypes of multidrug-resistant (MDR) *E. coli* among UTI isolates, we launched a project to establish a province network for continuous monitoring of such resistance among *E. coli* isolated from urine at five hospital laboratories which are affiliated to Kurdistan University of Medical Sciences, Sanandaj, Iran.

MATERIALS AND METHODS

Five hospital microbiology laboratories were participated in the study. In charge of each hospital laboratory was asked to come for a meeting concerning the collection of urine specimen, isolation, identification and antimicrobial susceptibility procedure for *E. coli*, in order to have the same procedures in all the laboratories. *E. coli* PTCC 1533 was sent to them as a positive control for antimicrobial susceptibility testing.

Isolation and identification of *E. coli*

Isolation and identification of *E. coli* to the species level was performed by standard methods⁹.

Antibiotic susceptibility of *E. coli* isolates

Testing procedures were validated following the Kirby-Bauer disc diffusion technique using Muller Hinton agar¹⁰. For each isolate, antibiotic susceptibility was determined for 11 different antibiotics: Ampicillin, Amikacin, Tetracycline, Amoxycillin, Chloramphenicol, Co-trimoxazole, Nalidixic acid, Ciprofloxacin, Nitrofurantoin, Cefotaxime, Imipenem, and Gentamycin.

Screening test for ESBL was done according to the criteria recommended by CLSI¹⁰. Briefly, we used CPM and CPM/clavulanic acid, CAZ and CAZ/clavulanic acid and CTX and CTX/clavulanic acid disks (MAST). After inoculating isolates in Muller-Hinton Agar (Merck, Germany) plates and 24 hours incubation, zones for compound disks larger than or equal to five mm compared with single disks, considered as producing ESBLs.

RESULTS

A total of 1257 *E. coli* strains were isolated from patients who suffer from UTI referred to five hospitals in Kurdistan province. The most resistant antibiotics tested against *E. coli* were tetracycline, amoxicillin and chloramphenicol (Table 1). All the *E. coli* isolates were tested for ESBL production and 239 (19.02%) were found to be ESBL producers (Fig. 1).

DISCUSSION

Antimicrobial resistance often leads to therapeutic failure of empirical therapy; therefore, knowledge of the local prevalence of pathogens and their antimicrobial sensitivity patterns is essential for clinicians in their routine work. Clinicians should also be aware of the sensitivity patterns in both neighboring and distant areas.

This study reveals the antibiotic susceptibility pattern and ESBL prevalence in *E. coli* isolated from patients suffering from UTIs in Kurdistan province, Iran. Majority (76.13%) of *E. coli* were isolated from female patients (Data not shown); an observation similar to other reports¹¹⁻¹².

In the present investigation, high resistance of *E. coli* to numerous antibiotics was observed. These results are congruent to the results reported in Nigeria and Iran¹³⁻¹⁴, who found more than 90% resistance of their *E. coli* isolates to ampicillin. The situation indicates a threat and a possibility that the *E. coli* could have become resistance to many more antibiotics to which it showed susceptibility earlier.

ESBL are now a significant problem in hospitalized patients throughout the world. The prevalence of ESBLs among clinical isolates varies greatly worldwide and patterns are rapidly changing over time¹⁵.

By screening test for ESBL, 19.02% of *E. coli*, were found to be positive. Our study showed a lower percentage of ESBL producers when compared to reports of Babypadmini and Appalaraju¹¹, but was almost in concordance with Ava Behroozzi et al¹⁴.

In conclusion, our study reinforces the necessity for appropriate use of antibiotics, and with the technical ability we now have to see resistance at a genetic level, to monitor more detailed patterns of emergence. Guidelines for the early phenotypic detection of ESBL in microbiology laboratories are needed.

Table 1: Antibiotic resistance pattern of *E. coli* strains isolated from urine specimens at five hospitals in Kurdistan Province.

Antibiotics	Resistance (%)
Ampicillin	84.97
Amikacin	42.33
Tetracycline	89.89
Amoxycillin	87.51
Chloramphenicol	86.0
Co-trimoxazole	75.02
Nalidixic acid	75.02
Ciprofloxacin	19.97
Nitrofurantion	19.97
Cefotaxime	32.54
Imipenem	10.03
Gentamycin	45.03
Carbanicillin	27.53




Fig 1: Phenotypic detection of ESBL by DDST among *E. coli* strains isolated from urine specimens at five hospitals in Kurdistan Province.

Acknowledgments

The authors wish to thank the following individuals for their assistance in the execution of this study: Dr. Estifaei F, Rashidi S and Amjadian P. This study was funded partly by a research grant from Kurdistan University of Medical Sciences, Sanandaj, Iran.

REFERENCES

- Ronald A.R., Nicolle, L.E., Stamm E. Urinary tract infection in adults: research priorities and strategies. *Int. J. Antimicrob. Agents* 2001;17:343-8.
- Van Eldere, J. Multicentre surveillance of *Pseudomonas aeruginosa* susceptibility patterns in nosocomial infections. *J. Antimicrob. Chemother.* 2003; 51(2):347-352.
- Miranda S, Davide M, Peter J. Evolution of multi-resistance plasmids in Australia clinical isolates of *Escherichia coli*. *Microbiology*. 2004;150: 1539-1546.
- Hassan S. Sensitivity of *Salmonella* and *Shigella* to antibiotics and chemotherapeutic agents in Sudan. *J. Trop. Med. Hyg.* 1995; 88: 243-248.
- Pitout, J. D., P. Nordmann, K. B. Laupland, and L. Poirel. Emergence of Enterobacteriaceae producing extended-spectrum β -lactamases (ESBLs) in the community. *J. Antimicrob. Chemother.* 2005;56:52-59.
- Astal Z, Sharif FA, Abdallah SA, Fahd MI. Extended spectrum beta-lactamases in *E. coli* isolated from community-acquired urinary tract infections in the Gaza Strip, Palestine. *Ann Saudi Med.* 2004;24: 55-57.
- World Health Organization Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997. WHO/TB/97-229. Geneva: The Organization; 1997.
- O'Brien T. The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. *Clinical infectious diseases*. 1997; 24 (suppl. 1): S2-S8.
- Mackie and Mc Cartney. *Practical Medical Microbiology*, 2007; 13th edition; p.171-172.
- Clinical and Laboratory Standards Institute: 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI/NCCLS M100-S20. 3 (1): Clinical and Laboratory Standards Institute, Wayne, Pa.
- Babypadmini S, Appalaraju B. Extended spectrum β -lactamases in urinary isolates of *Escherichia coli* and *Klebsiella pneumoniae* – prevalence and susceptibility pattern in a tertiary care hospital. *Indian Journal of Medical Microbiology*. 2004; 22 (3):172-174.
- Odusanya O. Antibiotic susceptibility of microorganisms at a general hospital in Lagos, Nigeria. *Journal of the National Medical Association*. 2002;49(11): 994-998.
- Umolu P. Idia, Omigie O., Tاتفeng Y., Omorogbe F.I., Aisabokhale F, Ugboogah O. P. Antimicrobial Susceptibility and Plasmid Profiles of *Escherichia coli* Isolates Obtained from Different Human Clinical Specimens in Lagos – Nigeria. *Journal of American Science*. 2006;2(4):70-75.
- Ava Behroozzi, Mohammad Rahbar and Jalil Vand Yousefi. Frequency of extended spectrum beta-lactamase (ESBLs) producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from urine in an Iranian 1000-bed tertiary care hospital. 2010. *African Journal of Microbiology Research*. 2010; 4 (9): 881-884.
- Mohamudha P, Subha Manivannan, Harish B, Parija C. Study of CTX-M Type of Extended Spectrum β -Lactamase among Nosocomial Isolates of *Escherichia coli* and *Klebsiella pneumoniae* in South India. *Indian J Microbiol.* 2011; DOI 10.1007/s12088-011-0140-3.